zentalis board of directors

Posted on

NEW YORK & SAN DIEGO Zentalis Pharmaceuticals (the Company or Zentalis), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors.Mr. Implicit in this philosophy is the importance of sound corporate governance. post or otherwise publish any content unrelated to the board or the board's topic. Melissa Epperly has served as Chief Financial Officer at Zentalis Pharmaceuticals, Inc., a clinical-stage cancer company, since September 2019. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 10835 Road to the Cure Suite 205 San Diego, CA 92121. Item 5.02. Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. Item 5.02. On May 25, 2022, the Board of Directors (the "Board") of Zentalis Pharmaceuticals, Inc. (the "Company") appointed Cam S. Gallagher, a current Executive Director of the Company and a current member of the Board, as President of the Company, succeeding Kimberly Blackwell in such role, effective as of May 30, 2022 (the "Commencement Date"). Notice to Search Firms/Third-Party Recruitment Agencies (Recruiters) The Human Resources team manages the recruitment and employment process for Zentalis Pharmaceuticals, Inc. (Zentalis) To protect the interest of all parties involved, Zentalis will only accept resumes from a recruiter if an executed search agreement is in place at the start of the recruitment effort. January 09, 2020 08:00 AM Eastern Standard Time. I would like to thank Pat Machado for his contributions to the Board and Roivant over the past six years. Melissa Epperly has served as Chief Financial Officer at Zentalis Pharmaceuticals, Inc., a clinical-stage cancer company, since September 2019. Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors. Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. Dr. Blackwell has been an independent director of Zentalis since 2020. The average salary for Director of Philanthropy at companies like ZENTALIS PHARMACEUTICALS INC in the United States is $169,600 as of April 26, 2022, but the range typically falls between $144,400 and $199,700. NEW YORK & SAN DIEGO-- ( BUSINESS WIRE )-- Zentalis Pharmaceuticals (the Company or Zentalis), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. Posted on 07/01/2020 72 . Company profile for Zentalis Pharmaceuticals Inc. including key executives, insider trading, ownership, revenue and average growth rates. About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Dr. Kariuki is a highly accomplished finance Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. 734th out of 1,418 stocks. Mr. USA, NY Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. 10835 Road to the Cure Suite 205 San Diego, CA 92121. Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. Pharmaceutical Preparations Industry. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of re-post premium share chat posts on regular share chat. She brings extensive experience as a senior financial executive in the life sciences industry. Board members at this company Cam S. Gallagher David M. Johnson Kimberly Blackwell As a member of Board of Directors at Zentalis Pharmaceuticals, Inc. , Cam S. Gallagher made $3,339,132 in total compensation. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Download PDF. Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors /EIN News/ -- NEW YORK and SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological 1-212-433-3791 info@zentalis.com Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells Adam Schayowitz, Ph.D., MBA, Vice President & Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma, Pfizer, to join Zentalis Scientific Advisory Board We are excited to welcome David to our board as he brings his

He will report to Chief Executive Officer Dr. Kimberly Blackwell. Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. 357th out of 679 stocks Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board. Investors/Media Home Company Profile. Zentalis Pharmaceuticals is a New York City and San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting fundamental biological pathways of cancer. Johnson is a veteran USA, NY Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Dr. Enoch Kariuki, PharmD, to its Board of Directors. I would like to thank Pat Machado for his contributions to the Board and Roivant over the past six years . Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors. On June 30, 2022, the Board of Directors (the "Board") of BioXcel Therapeutics, Inc. (the "Company") appointed Michael Miller to the Board, 65, has served as an advisor to pharmaceutical companies, Zentalis Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc., since July 2021 and September 2020, respectively. USA, NY Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Dr Kimberly Blackwell to its Board of Directors. On June 30, 2022, the Board of Directors (the "Board") of BioXcel Therapeutics, Inc. (the "Company") appointed Michael Miller to the Board, 65, has served as an advisor to pharmaceutical companies, Zentalis Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc., since July 2021 and September 2020, respectively. About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. On May 25, 2022, the Board of Directors (the "Board") of Zentalis Pharmaceuticals, Inc. (the "Company") appointed Cam S. Gallagher, a current Executive Director of the Company and a current member of the Board, as President of the Company, succeeding Kimberly Blackwell in such role, effective as of May 30, 2022 (the "Commencement Date"). Non-employee members of the board of directors (the Board) of Zentalis Pharmaceuticals, Inc. (the Company) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this Program), as amended by the Board effective March 18, 2021 (the Effective Date).This Program has been adopted under the Companys 2020 Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. Non-employee members of the board of directors (the Board) of Zentalis Pharmaceuticals, Inc. (the Company) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this Program).This Program has been adopted under the Companys 2020 Incentive Award Plan (the Equity Plan) and shall be NEW YORK and SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological We are pleased to welcome Enoch to our Board of Directors, and believe his--Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical See the breakdown of the total annual compensation for David M. Johnson for being a board member of ZENTALIS PHARMACEUTICALS INC, as well as other members of the Board of Directors for ZENTALIS PHARMACEUTICALS INC Gallagher, who previously served as an Executive Director of Zentalis, will remain a member of the Board of Directors, which he has served on since the Companys founding. In addition, Board member Dave Johnson has been appointed Chairman. The Board of Directors of Zentalis Pharmaceuticals. Dr. Blackwell is a current member of Zentalis Board and previously served as Chief Medical Officer of Tempus Labs and held clinical development leadership roles at Eli Lilly and Company. Please contact us at bd@ null zentalis.com to discuss partnering and collaborations opportunities. Anthony has played an active role across the life science industry since 2002 and currently serves as President and Chief Executive Officer for Zentalis Pharmaceuticals. Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. For More Information. The AP news staff was not involved in its creation. (the "Company") sets high standards for the Company's employees, officers and directors. Zentalis Pharmaceuticals (the Company or Zentalis), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. Medical Sector. Jan 9, 2020 at 8:00 AM EST. On May 10, 2022, | July 3, 2022 About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Learn about the executive team and board of directors at Zentalis Pharmaceuticals Inc Ordinary Shares (ZNTL:XNAS) and review their bios and compensation over the latest fiscal years. Press release content from Business Wire. President and Director of Zentalis Pharmaceuticals. Zentalis Pharmaceuticals Appoints David Johnson to Board of Directors Explore New York business news Jan 9 2020 BoardMoves Mr. Johnson is a veteran biopharmaceutical and healthcare leader with more than 25 years of experience in developing drugs and On May 10, 2022, | July 3, 2022 Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells Adam Schayowitz, Ph.D., MBA, Vice President & Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma, Pfizer, to join Zentalis Scientific Advisory Board (the "Company") sets high standards for the Company's employees, officers and directors. Dr Wollowick is the Sr. Director of Business Liked by Yelena Lalazar (Blumshtein) I was 17 years old when I was forced into an arranged marriage. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. See the breakdown of the total annual compensation for Kimberly Blackwell for being a board member of ZENTALIS PHARMACEUTICALS INC, as well as other members of the Board of Directors for ZENTALIS PHARMACEUTICALS INC The Pfizer Board Policies Ensuring ethical leadership Corporate Governance FAQs Learn more about our approach Contact Our Directors Email any of our Directors History; Careers. Research and Business Development Partnerships Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer. Dr. Science Center. NEW YORK & SAN DIEGO Zentalis Pharmaceuticals (the Company or Zentalis), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. Michelle Arthur Associate Director Pharmacovigilance at Zentalis Pharmaceuticals Somerville, New Jersey, United States 298 connections Sun serves as Chief Executive Officer and a member of the board of directors of Zentera, the Companys joint venture in China and Kalyra Pharmaceuticals, Inc., or Kalyra, a small molecule drug discovery and Zentalis Pharmaceuticals Appoints David Johnson to Board of Directors. Name Total COMPENSATION; Cam S. Gallagher: Total Cash $3,339,132: David M. Johnson: Zentalis provides equal employment opportunity to all employees and applicants without regard to an individuals protected status. She brings extensive experience as a senior financial executive in the life sciences industry. Dr. Blackwell is a renowned breast cancer We are pleased to welcome Enoch to our Board of Directors, and believe his--Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical USA, NY Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Dr Kimberly Blackwell to its Board of Directors. Item 5.02. USA, NY Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. He will report to Chief Executive Officer Dr. Kimberly Blackwell. Sun, M.D., has served as the Companys President and Chief Executive Officer and Chairman of the Companys Board of Directors since December 2014. The Board of Directors of Zentalis Pharmaceuticals. President and Director of Zentalis Pharmaceuticals. Corporate Governance Overview. Search Jobs; Connect With Us; Partners. Zentalis intends to use the net proceeds of the offering to help fund ongoing and planned clinical trials, including studies of ZN-c3, its Wee1 inhibitor, and ZN-d5, its BCL-2 inhibitor, and for working capital and general corporate purposes. The Board of Directors (the Board) of Zentalis Pharmaceuticals, Inc. (the Company) has adopted the following Corporate Governance Guidelines (the Guidelines) to assist the Board in the exercise of its responsibilities and to serve the interests of the Company and its stockholders. Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors. Board of Directors in Zentalis Pharmaceuticals, Inc. For its 2020 fiscal year, Zentalis Pharmaceuticals, Inc., listed the following board members on its annual proxy statement to the SEC. Zentalis Pharmaceuticals (the Company or Zentalis), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. For More Information. Anthony Y. 10275 Science Center Drive Suite 200 San Diego, CA 92121 Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Enoch Kariuki, PharmD, to its Board of Directors Implicit in this philosophy is the importance of sound corporate governance. On June 21, 2022, Alexis M. Pinto notified Zentalis Pharmaceuticals, Inc. (the "Company") of her resignation as Chief Legal Officer and Secretary of the Company, effective as of July 5, 2022. Matricelf is happy to announce that Adam Wollowick MD/MBA is joining its scientific advisory board. We are excited to welcome David to our board as he brings his Zentalis Pharmaceuticals Appoints David Johnson to Board of Directors. Gallagher, who previously served as an Executive Director of Zentalis, will remain a member of the Board of Directors, which he has served on since the Companys founding. 1-212-433-3791 info@zentalis.com restrict or inhibit any other user from using the boards. View detailed ZNTL.US description & address.